2nd Edition of International Cancer & Immuno-Oncology Conference
March 19-21, 2026 | Singapore
Anticancer Drug Development
Anticancer drug development stands at the forefront of cancer research, aiming to revolutionize treatment modalities and improve patient outcomes. Scientists employ various innovative approaches, including targeted therapies, immunotherapy, and precision medicine, to combat cancer's heterogeneous nature. Targeted therapies selectively attack cancer cells while sparing healthy tissues, minimizing side effects. Immunotherapy harnesses the body's immune system to recognize and destroy cancer cells, offering promising results across diverse cancer types. Furthermore, precision medicine tailors treatment strategies based on individual genetic profiles, optimizing efficacy and minimizing resistance. Collaborative efforts between researchers, clinicians, and pharmaceutical companies drive the relentless pursuit of novel anticancer agents, offering hope for enhanced survival rates and improved quality of life for cancer patients worldwide.
Rajvir Dahiya
University of California San Francisco, United States
Atif A Ahmed
University of Washington-Seattle Children’s Hospital, United States
Anyou Wang
DIFIBER LLC, United States
Paulo Cesar De Morais
Catholic University of Brasilia, Brazil
Allen Chen
Olympic Medical Center, United States
Shilpa S Dhar
UT MD Anderson Cancer Center, United States
Ritu Khanna
University of Manchester, United KingdomSubmit your abstract Today
Title : A novel blood-based mRNA genomics technology for cancer diagnosis and treatment
Rajvir Dahiya, University of California San Francisco, United States
Title : tRNA-derived fragment 3′tRF-AlaAGC modulates cell chemoresistance and M2 macrophage polarization via binding to TRADD in breast cancer
Feng Yan, The Affiliated Cancer Hospital of Nanjing Medical University, China
Title : Integrating single-cell and spatial transcriptomics to uncover and elucidate GP73-mediated pro-angiogenic regulatory networks in hepatocellular carcinoma
Jiazhou Ye, Guangxi Medical University Cancer Hospital, China
Title : Unveiling the synergism of radiofrequency therapy and graphene nanocomposite in tumor cell viability assay
Paulo Cesar De Morais, Catholic University of Brasilia, Brazil
Title : Analysis of the dynamic evolution and influencing factors of nutritional risk in breast cancer patients during treatment
Jingwen Yan, Sun Yat-sen University, China
Title : Integrative multi-omics reveals metabolic–stemness coupling and novel therapeutic targets in osteosarcoma chemoresistance
Jinyan Feng, Tianjin Medical University Cancer Institute and Hospital, China